Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Effects of acute fructose loading on levels of serum uric acid-a pilot study.

Olofsson C, Anderstam B, Bragfors-Helin AC, Eriksson M, Qureshi AR, Lindholm B, Hilding A, Wiczkowski W, Orsini N, Stenvinkel P, Rajamand Ekberg N.

Eur J Clin Invest. 2019 Jan;49(1):e13040. doi: 10.1111/eci.13040. Epub 2018 Nov 16.

PMID:
30368775
2.

Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study.

Levin A, Nair D, Qureshi AR, Bárány P, Heimburger O, Anderstam B, Stenvinkel P, Bruchfeld A, Ungerstedt JS.

Nephron. 2018;140(4):249-256. doi: 10.1159/000492500. Epub 2018 Sep 25.

PMID:
30253414
3.

Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients.

Molanaei H, Qureshi AR, Heimbürger O, Lindholm B, Diczfalusy U, Anderstam B, Bertilsson L, Stenvinkel P.

BMC Pharmacol Toxicol. 2018 Jun 25;19(1):33. doi: 10.1186/s40360-018-0221-6.

4.

Brown adipose tissue in young adults who were born preterm or small for gestational age.

Kistner A, Rydén H, Anderstam B, Hellström A, Skorpil M.

J Pediatr Endocrinol Metab. 2018 Jun 27;31(6):641-647. doi: 10.1515/jpem-2017-0547.

PMID:
29729148
5.

Restrictive lung disorder is common in patients with kidney failure and associates with protein-energy wasting, inflammation and cardiovascular disease.

Mukai H, Ming P, Lindholm B, Heimbürger O, Barany P, Anderstam B, Stenvinkel P, Qureshi AR.

PLoS One. 2018 Apr 27;13(4):e0195585. doi: 10.1371/journal.pone.0195585. eCollection 2018.

6.

Skin autofluorescence, arterial stiffness and Framingham risk score as predictors of clinical outcome in chronic kidney disease patients: a cohort study.

Mukai H, Svedberg O, Lindholm B, Dai L, Heimbürger O, Barany P, Anderstam B, Stenvinkel P, Qureshi AR.

Nephrol Dial Transplant. 2019 Mar 1;34(3):442-448. doi: 10.1093/ndt/gfx371.

PMID:
29378035
7.

Plasma Beta-Trace Protein as a Marker of Residual Renal Function: The Effect of Different Hemodialysis Modalities and Intra-Individual Variability over Time.

van Craenenbroeck AH, Bragfors-Helin AC, Qureshi AR, Lindholm B, Sjöberg B, Anderstam B, Heimburger O, Stenvinkel P, Bárány P.

Kidney Blood Press Res. 2017;42(5):877-885. doi: 10.1159/000484537. Epub 2017 Nov 22.

8.

Plasma Pentosidine and Its Association with Mortality in Patients with Chronic Kidney Disease.

Machowska A, Sun J, Qureshi AR, Isoyama N, Leurs P, Anderstam B, Heimburger O, Barany P, Stenvinkel P, Lindholm B.

PLoS One. 2016 Oct 4;11(10):e0163826. doi: 10.1371/journal.pone.0163826. eCollection 2016.

9.

Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis.

Bergman A, Qureshi AR, Haarhaus M, Lindholm B, Barany P, Heimburger O, Stenvinkel P, Anderstam B.

J Nephrol. 2017 Apr;30(2):255-262. doi: 10.1007/s40620-016-0292-7. Epub 2016 Mar 18.

PMID:
26994005
10.

Autologous Peripheral Blood Mononuclear Cells as Treatment in Refractory Acute Respiratory Distress Syndrome.

Jungebluth P, Holzgraefe B, Lim ML, Duru AD, Lundin V, Heldring N, Wiklander OP, Nordin JZ, Chrobok M, Roderburg C, Sjöqvist S, Anderstam B, Beltrán Rodríguez A, Haag JC, Gustafsson Y, Roddewig KG, Jones P, Wood MJ, Luedde T, Teixeira AI, Hermanson O, Winqvist O, Kalzén H, El Andaloussi S, Alici E, Macchiarini P.

Respiration. 2015;90(6):481-92. doi: 10.1159/000441799. Epub 2015 Nov 28.

11.

Elevated Circulating S100A12 Associates with Vascular Disease and Worse Clinical Outcome in Peritoneal Dialysis Patients.

Isoyama N, Machowska A, Qureshi AR, Yamamoto T, Anderstam B, Heimburger O, Barany P, Stenvinkel P, Lindholm B.

Perit Dial Int. 2016 May-Jun;36(3):269-76. doi: 10.3747/pdi.2014.00121. Epub 2015 Oct 22.

12.

Cholinergic anti-inflammatory pathway activity in dialysis patients: a role for neuroimmunomodulation?

Hilderman M, Qureshi AR, Al-Abed Y, Abtahi F, Lindecrantz K, Anderstam B, Bruchfeld A.

Clin Kidney J. 2015 Oct;8(5):599-605. doi: 10.1093/ckj/sfv074. Epub 2015 Aug 25.

13.

Genetic, epigenetic and protein analyses of intercellular adhesion molecule 1 in Malaysian subjects with type 2 diabetes and diabetic nephropathy.

Abu Seman N, Anderstam B, Wan Mohamud WN, Östenson CG, Brismar K, Gu HF.

J Diabetes Complications. 2015 Nov-Dec;29(8):1234-9. doi: 10.1016/j.jdiacomp.2015.07.004. Epub 2015 Jul 22.

PMID:
26255081
14.

Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.

Isoyama N, Leurs P, Qureshi AR, Bruchfeld A, Anderstam B, Heimburger O, Bárány P, Stenvinkel P, Lindholm B.

Nephrol Dial Transplant. 2015 Jan;30(1):84-91. doi: 10.1093/ndt/gfu259. Epub 2014 Jul 28.

PMID:
25074436
15.

Oxidative DNA damage and mortality in hemodialysis and peritoneal dialysis patients.

Xu H, Watanabe M, Qureshi AR, Heimbürger O, Bárány P, Anderstam B, Eriksson M, Stenvinkel P, Lindholm B.

Perit Dial Int. 2015 Mar-Apr;35(2):206-15. doi: 10.3747/pdi.2013.00259. Epub 2014 Mar 1.

16.

Increased Levels of Modified Advanced Oxidation Protein Products Are Associated with Central and Peripheral Blood Pressure in Peritoneal Dialysis Patients.

Xu H, Cabezas-Rodriguez I, Qureshi AR, Heimburger O, Barany P, Snaedal S, Anderstam B, Helin AC, Carrero JJ, Stenvinkel P, Lindholm B.

Perit Dial Int. 2015 Jul-Aug;35(4):460-70. doi: 10.3747/pdi.2013.00064. Epub 2014 Mar 1.

17.

Evaluation of the association of plasma pentraxin 3 levels with type 2 diabetes and diabetic nephropathy in a Malay population.

Abu Seman N, Witasp A, Wan Mohamud WN, Anderstam B, Brismar K, Stenvinkel P, Gu HF.

J Diabetes Res. 2013;2013:298019. doi: 10.1155/2013/298019. Epub 2013 Nov 20.

18.

Metabolic changes in summer active and anuric hibernating free-ranging brown bears (Ursus arctos).

Stenvinkel P, Fröbert O, Anderstam B, Palm F, Eriksson M, Bragfors-Helin AC, Qureshi AR, Larsson T, Friebe A, Zedrosser A, Josefsson J, Svensson M, Sahdo B, Bankir L, Johnson RJ.

PLoS One. 2013 Sep 9;8(9):e72934. doi: 10.1371/journal.pone.0072934. eCollection 2013.

19.

Circulating vascular endothelial growth factor (VEGF) and its soluble receptor 1 (sVEGFR-1) are associated with inflammation and mortality in incident dialysis patients.

Yuan J, Guo Q, Qureshi AR, Anderstam B, Eriksson M, Heimbürger O, Bárány P, Stenvinkel P, Lindholm B.

Nephrol Dial Transplant. 2013 Sep;28(9):2356-63. doi: 10.1093/ndt/gft256. Epub 2013 Jul 4.

PMID:
23828162
20.

Macrophage migration inhibitory factor (MIF) and thyroid hormone alterations in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Wendt M, Börjesson O, Avik A, Bratt J, Anderstam B, Qureshi AR, Miller EJ, Gunnarsson I, Bruchfeld A.

Mol Med. 2013 May 20;19:109-14. doi: 10.2119/molmed.2012.00352.

21.

Differences in acute metabolism of fructose between hemodialysis patients and healthy subjects.

Anderstam B, Bragfors-Helin AC, Axelsson J, Qureshi AR, Wibom R, Lindholm B, Stenvinkel P.

Scand J Clin Lab Invest. 2013 Mar;73(2):154-60. doi: 10.3109/00365513.2012.758386. Epub 2013 Jan 22.

PMID:
23336588
22.

Pentraxin 3, a sensitive early marker of hemodialysis-induced inflammation.

Sjöberg B, Qureshi AR, Anderstam B, Alvestrand A, Bárány P.

Blood Purif. 2012;34(3-4):290-7. doi: 10.1159/000342630. Epub 2012 Dec 7.

PMID:
23235124
23.

Changes in circulating biomarkers during a single hemodialysis session.

Yamamoto T, Nascimento MM, Hayashi SY, Qureshi AR, Waniewski J, Brodin LÅ, Anderstam B, Lind B, Riella MC, Seeberger A, Lindholm B.

Hemodial Int. 2013 Jan;17(1):59-66. doi: 10.1111/j.1542-4758.2012.00720.x. Epub 2012 Jun 20.

PMID:
22716238
24.
25.

Circulating follistatin in patients with chronic kidney disease: implications for muscle strength, bone mineral density, inflammation, and survival.

Miyamoto T, Carrero JJ, Qureshi AR, Anderstam B, Heimbürger O, Bárány P, Lindholm B, Stenvinkel P.

Clin J Am Soc Nephrol. 2011 May;6(5):1001-8. doi: 10.2215/CJN.10511110. Epub 2011 Feb 24.

26.

Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients.

Nakashima A, Carrero JJ, Qureshi AR, Miyamoto T, Anderstam B, Bárány P, Heimbürger O, Stenvinkel P, Lindholm B.

Clin J Am Soc Nephrol. 2010 Dec;5(12):2213-9. doi: 10.2215/CJN.03360410. Epub 2010 Sep 16.

27.

Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients.

Chmielewski M, Bragfors-Helin AC, Stenvinkel P, Lindholm B, Anderstam B.

Clin Chim Acta. 2010 Dec 14;411(23-24):2079-82. doi: 10.1016/j.cca.2010.09.009. Epub 2010 Sep 16.

PMID:
20837002
28.

Associations between amino acids and bone mineral density in men with idiopathic osteoporosis.

Pernow Y, Thorén M, Sääf M, Fernholm R, Anderstam B, Hauge EM, Hall K.

Bone. 2010 Nov;47(5):959-65. doi: 10.1016/j.bone.2010.08.017. Epub 2010 Sep 8.

PMID:
20813216
29.

Clinical importance of an elevated circulating chemerin level in incident dialysis patients.

Yamamoto T, Qureshi AR, Anderstam B, Heimbürger O, Bárány P, Lindholm B, Stenvinkel P, Axelsson J.

Nephrol Dial Transplant. 2010 Dec;25(12):4017-23. doi: 10.1093/ndt/gfq329. Epub 2010 Jun 13.

PMID:
20543210
30.

Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study.

Nascimento MM, Suliman ME, Silva M, Chinaglia T, Marchioro J, Hayashi SY, Riella MC, Lindholm B, Anderstam B.

Perit Dial Int. 2010 May-Jun;30(3):336-42. doi: 10.3747/pdi.2009.00073. Epub 2010 Feb 26.

PMID:
20190028
31.

Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels.

Carrero JJ, Witasp A, Stenvinkel P, Qureshi AR, Heimbürger O, Bárány P, Suliman ME, Anderstam B, Lindholm B, Nordfors L, Schalling M, Axelsson J.

Nephrol Dial Transplant. 2010 Mar;25(3):901-6. doi: 10.1093/ndt/gfp587. Epub 2009 Nov 30.

PMID:
19948877
32.

Bicarbonate-based peritoneal dialysis solution has less effect on ingestive behavior than lactate-based peritoneal dialysis solution.

Zheng ZH, Anderstam B, Yu X, Qureshi AR, Heimbürger O, Lindholm B.

Perit Dial Int. 2009 Nov-Dec;29(6):656-63.

PMID:
19910567
33.

Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients.

Guo Q, Carrero JJ, Yu X, Bárány P, Qureshi AR, Eriksson M, Anderstam B, Chmielewski M, Heimbürger O, Stenvinkel P, Lindholm B, Axelsson J.

Nephrol Dial Transplant. 2009 Nov;24(11):3468-73. doi: 10.1093/ndt/gfp315. Epub 2009 Jun 26.

PMID:
19561151
34.

The kidney is the major site of S-adenosylhomocysteine disposal in humans.

Garibotto G, Valli A, Anderstam B, Eriksson M, Suliman ME, Balbi M, Rollando D, Vigo E, Lindholm B.

Kidney Int. 2009 Aug;76(3):293-6. doi: 10.1038/ki.2009.117. Epub 2009 Apr 8.

35.

Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin-A in chronic kidney disease.

Suliman ME, García-López E, Anderstam B, Lindholm B, Stenvinkel P.

Adv Clin Chem. 2008;46:217-62. Review.

PMID:
19004191
36.

Amino acid profiles in adults with growth hormone (GH) deficiency before and during GH replacement therapy.

Fernholm R, Thoren M, Hoybye C, Anderstam B, Pernow Y, Saaf M, Hall K.

Growth Horm IGF Res. 2009 Jun;19(3):206-11. doi: 10.1016/j.ghir.2008.09.001. Epub 2008 Nov 6.

PMID:
18990596
37.

Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients.

Valli A, Carrero JJ, Qureshi AR, Garibotto G, Bárány P, Axelsson J, Lindholm B, Stenvinkel P, Anderstam B, Suliman ME.

Clin Chim Acta. 2008 Sep;395(1-2):106-10. doi: 10.1016/j.cca.2008.05.018. Epub 2008 Jun 27.

PMID:
18565329
38.

Rate of synthetic oligosaccharide degradation as a novel measure of amylase activity in peritoneal dialysis patients.

García-López E, Werynski A, Heimbürger O, Filho JC, Lindholm B, Anderstam B.

Perit Dial Int. 2008 May-Jun;28(3):296-304.

PMID:
18474923
39.

Amino-acid-based peritoneal dialysis solution improves amino-acid transport into skeletal muscle.

Asola M, Virtanen K, Någren K, Helin S, Taittonen M, Kastarinen H, Anderstam B, Knuuti J, Metsärinne K, Nuutila P.

Kidney Int Suppl. 2008 Apr;(108):S131-6. doi: 10.1038/sj.ki.5002614.

40.

Modification of the oxidative stress biomarker AOPP assay: application in uremic samples.

Anderstam B, Ann-Christin BH, Valli A, Stenvinkel P, Lindholm B, Suliman ME.

Clin Chim Acta. 2008 Jul 17;393(2):114-8. doi: 10.1016/j.cca.2008.03.029. Epub 2008 Apr 1.

PMID:
18423381
41.

Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro--towards a standardized approach for research on uraemia.

Cohen G, Glorieux G, Thornalley P, Schepers E, Meert N, Jankowski J, Jankowski V, Argiles A, Anderstam B, Brunet P, Cerini C, Dou L, Deppisch R, Marescau B, Massy Z, Perna A, Raupachova J, Rodriguez M, Stegmayr B, Vanholder R, Hörl WH; European Uremic Toxin Work Group (EUTox).

Nephrol Dial Transplant. 2007 Dec;22(12):3381-90. Epub 2007 Aug 27. Review. No abstract available. Erratum in: Nephrol Dial Transplant. 2008 Feb;23(2):780.

PMID:
17724037
42.

Peritoneal transport in peritoneal dialysis patients using glucose-based and amino acid-based solutions.

Olszowska A, Waniewski J, Werynski A, Anderstam B, Lindholm B, Wankowicz Z.

Perit Dial Int. 2007 Sep-Oct;27(5):544-53.

PMID:
17704445
43.

Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality.

Tong M, Carrero JJ, Qureshi AR, Anderstam B, Heimbürger O, Bárány P, Axelsson J, Alvestrand A, Stenvinkel P, Lindholm B, Suliman ME.

Clin J Am Soc Nephrol. 2007 Sep;2(5):889-97. Epub 2007 Aug 16.

44.

Icodextrin metabolism and alpha-amylase activity in nonuremic rats undergoing chronic peritoneal dialysis.

García-López E, Pawlaczyk K, Anderstam B, Qureshi AR, Kuzlan-Pawlaczyk M, Heimbürger O, Werynski A, Lindholm B.

Perit Dial Int. 2007 Jul-Aug;27(4):415-23.

PMID:
17602150
45.

Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors.

Valli A, Suliman ME, Meert N, Vanholder R, Lindholm B, Stenvinkel P, Watanabe M, Barany P, Alvestrand A, Anderstam B.

Clin Chim Acta. 2007 Apr;379(1-2):87-94. Epub 2007 Jan 16.

PMID:
17292872
46.

Elevated serum 8-oxo-dG in hemodialysis patients: a marker of systemic inflammation?

Haghdoost S, Maruyama Y, Pecoits-Filho R, Heimburger O, Seeberger A, Anderstam B, Suliman ME, Czene S, Lindholm B, Stenvinkel P, Harms-Ringdahl M.

Antioxid Redox Signal. 2006 Nov-Dec;8(11-12):2169-73.

PMID:
17034359
47.

Effect of bicarbonate on muscle protein in patients receiving hemodialysis.

Löfberg E, Gutierrez A, Anderstam B, Wernerman J, Bergström J, Price SR, Mitch WE, Alvestrand A.

Am J Kidney Dis. 2006 Sep;48(3):419-29.

PMID:
16931215
48.

Comparison of kinetic characteristics of amino acid-based and dipeptide-based peritoneal dialysis solutions.

Weryński A, Waniewski J, Wang T, Anderstam B, Lindholm B, Bergström J.

Int J Artif Organs. 2006 Jul;29(7):681-90.

PMID:
16874673
49.

Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.

Sjöberg B, Anderstam B, Suliman M, Alvestrand A.

Am J Kidney Dis. 2006 Jan;47(1):60-71.

PMID:
16377386
50.

Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease.

Suliman ME, Qureshi AR, Stenvinkel P, Pecoits-Filho R, Bárány P, Heimbürger O, Anderstam B, Rodríguez Ayala E, Divino Filho JC, Alvestrand A, Lindholm B.

Am J Clin Nutr. 2005 Aug;82(2):342-9.

PMID:
16087977

Supplemental Content

Loading ...
Support Center